期刊文献+

检测和肽素及肌钙蛋白I对急性非ST段抬高型心肌梗死的早期诊断价值 被引量:33

Diagnosis value of copeptin and c Tn I in early diagnosis of non-ST-segment elevation myocardial infarction
下载PDF
导出
摘要 目的:评价检测和肽素(copeptin)及肌钙蛋白I(c Tn I)在急性非ST段抬高型心肌梗死(NSTEMI)早期诊断中的价值。方法:176例发病在6 h以内、疑诊NSTEMI的患者分为NSTEMI组40例、心绞痛组56例、其他诊断80例。ROC曲线评估和肽素及c Tn I的诊断性能。结果:(1)NSTEMI组和肽素水平、c Tn I阳性率明显高于其他各组(P<0.05)。(2)和肽素诊断临界点时为10.85 pmol/L,灵敏度为90%,特异度为64%。c Tn I诊断临界点为0.05 ng/m L时,灵敏度为42.5%,特异度为94.1%。(3)和肽素<10.85 pmol/L联合c Tn I<0.05 ng/m L对NSTEMI阴性预测值为97.7%。结论:联合检测和肽素及c Tn I对NSTEMI的早期诊断性能优于单独检测c Tn I。 Objective To investigate the diagnostic accuracy and the clinical usefulness of the combination of troponin I (cTnI) and copeptin detected in patients with suspected non-ST elevation myocardial infarction. Methods 176 patients presenting to the emergency departments with chest chocking or chest pain within 6 hours and without ST elevation on a 12-lead electrocardiogram (ECG) were enrolled in this study. The level of copeptin and cTnI was measured. The diagnosis was adjudicated by 2 independent experts.The diagnostic performance of them was assessed using ROC analysis, and the sensitivity and specificity of them were inferred based on the positive rate of two cardiac markers. Results (1)The levels of copeptin and cTnI in NSTEMI patients were markedly higher than other groups (P〈 0.05). (2)The AUCs of copeptin and cTnI were 0.846 and 0.683, and the 95%CI of two markers were 0.786 - 0.906 and 0.577 ~ 0.789, respectively. (3)Using 10.85 pmol/L as cut off value, the sensitivity and specificity of copeptin were 90% and 64% , and the positive predictive value and the negative predictive valueof NSTEMI diagnose were 42.4% and 95.6%, respectively.Using 0.05 ng/mL as cut off value, the sensitivity and specificity of cTnI were 42.5% and 94.1%, the positive predictive value and the negative predictive value were 68%and 84.8% for diagnosis of NSTEMI. (4)The copeptin level over 10.85 pmol/L in combination with cTnI could be used to detect NSTEMI with higher sensitivity than that of copeptin or cTnI alone (95% vs 90% vs 42.5%). The negative predictive value of the combination of copeptin and cTnI was increased, compared to that of copeptin or cTnI alone (97.7% vs 95.6% vs 85.7%). Conclusions Determination of copeptin in addition to cTnI can improves diagnostic performance, especially early after chest pain onset. It seems to allow a rapid and reliable rule out of NSTEMI.
出处 《实用医学杂志》 CAS 北大核心 2014年第19期3096-3099,共4页 The Journal of Practical Medicine
关键词 心肌梗死 和肽素 非ST段抬高 肌钙蛋白I 心绞痛 早期诊断 Myocardial Infarction Copeptin Non-ST Segment elevation cTnI Angina Early diagnosis
  • 相关文献

参考文献11

  • 1Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care [J]. Eur Heart J,2010,31(18) :2197-2204.
  • 2柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2143
  • 3朱海,秦忠.急性心肌梗死急诊经皮冠状动脉介入治疗对QT离散度的影响[J].岭南心血管病杂志,2013,19(6):692-694. 被引量:6
  • 4周启林,吴勤如,唐良秋.急性心肌梗死患者经皮冠状动脉介入治疗后尿水通道蛋白-2的变化及意义[J].岭南心血管病杂志,2013,19(6):695-697. 被引量:3
  • 5Morgenthaler NG, Struck J, Alonso C, et al. Assay for the inassurement of copeptin.A stable peptide derived from the precursor of vasopressin [J]. Clin Chem,2006,52 (1) : 112- 119.
  • 6Katan M, Morgenthaler N, Widmer I,et al.Copeptin,a stable peptide derived from the vasopress in precursor, correlates with the individual stress level [J]. Neum Endocrinol Lett, 2008,29 (3) : 341-346.
  • 7Nickel CH, Bingisser R, Morgenthaler NG, et al. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department [J ]. BMC Med, 2012, 10 (8) : 1741-1745.
  • 8Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function [J]. Congest Heart Fail,2010, 16 Suppl 1 :$37- 44.
  • 9Khan SQ, Dhillon OS, Quinn PA, et al. C-terminal provasopressin (copeptin)as a novel and prognostic marker in acute myocardial infarction : Leicester Acute MyocardialInfarction Peptide (LAMP) study [J]. Circulation,2007,115 (16) :2103- 2110.
  • 10Charpentier S, Maupas-Schwalm F, Coumot M, et al.Combination of copeptin and troponin assays to rapidly rule out non-ST elevation myocardial infarction in the emergency department [J]. Acad Emerg Med, 2012,19 (5) : 517-524.

二级参考文献39

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.

共引文献2148

同被引文献576

引证文献33

二级引证文献212

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部